Technical Analysis for MTCR - Metacrine, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Historical MTCR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Up | Strength | 0.10% | |
| Hot IPO Pullback | Bullish Swing Setup | 6.06% | |
| Inside Day | Range Contraction | 6.06% | |
| New 52 Week Closing Low | Bearish | 11.94% | |
| Multiple of Ten Bearish | Other | 11.94% | |
| Multiple of Ten Bullish | Other | 3.96% | |
| Hot IPO Pullback | Bullish Swing Setup | 2.54% | |
| New 52 Week Low | Weakness | 2.54% | |
| Multiple of Ten Bullish | Other | 2.54% | |
| Up 3 Days in a Row | Strength | 2.54% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Gap Up Closed | about 2 hours ago | |
| 60 Minute Opening Range Breakdown | about 2 hours ago | |
| Reversed from Up | about 2 hours ago | |
| Up 1% | about 3 hours ago | |
| Gapped Up (Partial) | about 3 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Metacrine is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. The company’s most advanced programs, MET409 and MET642, target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. Both MET409 and MET642 are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH).
Biopharmaceutical Life Sciences Diseases Chemical Compounds Specialty Drugs Hepatitis Non Alcoholic Fatty Liver Disease Steatohepatitis Carboxylic Acids Farnesoid X Receptor Gastrointestinal Disease
Biopharmaceutical Life Sciences Diseases Chemical Compounds Specialty Drugs Hepatitis Non Alcoholic Fatty Liver Disease Steatohepatitis Carboxylic Acids Farnesoid X Receptor Gastrointestinal Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.19 |
| 52 Week Low | 9.06 |
| Average Volume | 187,028 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 0.00 |
| Average True Range | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.29 | ||||
| Resistance 3 (R3) | 11.28 | 11.00 | 11.15 | ||
| Resistance 2 (R2) | 11.00 | 10.80 | 11.01 | 11.11 | |
| Resistance 1 (R1) | 10.75 | 10.68 | 10.88 | 10.76 | 11.06 |
| Pivot Point | 10.47 | 10.47 | 10.54 | 10.48 | 10.47 |
| Support 1 (S1) | 10.22 | 10.27 | 10.35 | 10.23 | 9.92 |
| Support 2 (S2) | 9.94 | 10.15 | 9.95 | 9.87 | |
| Support 3 (S3) | 9.69 | 9.94 | 9.83 | ||
| Support 4 (S4) | 9.70 |
